About: (Q)SAR modeling and safety assessment in regulatory review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: (Q)SAR modeling and safety assessment in regulatory review Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 18 January 2012

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articol științific (ro) articolo scientifico (it) artigo científico (gl) artigo científico (pt) artigo científico (pt-br) artikull shkencor (sq) artículo científico (es) artículu científicu (ast) bilimsel makale (tr) scienca artikolo (eo) vedecký článok (sk) vetenskaplig artikel (sv) vitenskapelig artikkel (nb) vitskapeleg artikkel (nn) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научная статья (ru) научни чланак (sr) מאמר מדעי (he) artikel ilmiah (id) article scientifique (fr) বৈজ্ঞানিক নিবন্ধ (bn) наукова стаття, опублікована в січні 2012 (uk) scientific article published on 18 January 2012 (en) scientific article published on 18 January 2012 (en-ca) scientific article published on 18 January 2012 (en-gb) مقالة علمية نشرت في 18 يناير 2012 (ar)
publication date	wds:Q37976993-3AC10A98-B7DF-4112-A9C5-2238FDEF5E50
publication date	2012-01-18 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37976993-4CA7821B-447F-4977-9452-400708997CE7
language of work or name	English
exact match	wds:Q37976993-A3CA2297-236D-43A1-B4E3-5230E8AF5515
exact match	https://scigraph.springernature.com/pub.10.1038/clpt.2011.300
cites work	wds:Q37976993-10FB9A01-0C3A-46B1-BF4C-17F6061BCFE5 wds:Q37976993-1FBF953A-E34A-4154-B252-975A256C2FF4 wds:Q37976993-22C8B5F1-7A9B-4A97-ABA1-572490F8B7DE wds:Q37976993-37409058-7315-420D-9CA8-75E47FE864A6 wds:Q37976993-3B4A480F-6D0D-4382-8C45-B6639D66D4E3 wds:Q37976993-4342FE84-C728-4C87-860D-8C09DFBCC956 wds:Q37976993-59CCF905-0E47-457C-9148-AB4A1D8E7BD4 wds:Q37976993-603EEB49-FFC0-43B1-800F-0D71CFE7CD6E wds:Q37976993-7C33EFF1-A799-424D-98B9-908B875BFF48 wds:Q37976993-7E224C32-60FA-4E9F-A8D4-098F5B1D691F wds:Q37976993-7F4A966C-14FA-4C26-99B9-069D98E5EC11 wds:Q37976993-819883FA-0AAB-40A6-810F-01F610F4905C wds:Q37976993-8F9C9AC7-E122-45BA-AB11-DDE22E0BA766 wds:Q37976993-9015B60B-4E29-43FF-B734-D64B0F4B2528 wds:Q37976993-9608D5C4-61A3-4DD5-B5B5-DD87F0938F91 wds:Q37976993-9614C676-8CAE-431A-80F9-42DB7FFE7F95 wds:Q37976993-A0D21189-15C9-4BA1-A020-3C3545E2FECB wds:Q37976993-A3D2CDC0-DF16-42B9-ACE8-CA93C85BFA29 wds:Q37976993-B4B51164-80BE-46E0-89B8-A11A16B6C22B wds:Q37976993-C2F8FE46-44DA-4E58-9716-0849E9C70AFF wds:Q37976993-C617CC2D-FD88-43A8-AF6F-FA5DAF3A12E4 wds:Q37976993-CDD31A44-5B3A-4B14-BC77-D18D411EA0D9 wds:Q37976993-CF021D56-2849-4B4E-8D57-E9135756F1BA wds:Q37976993-D6878E2C-6F38-429F-AEC7-7648D51E9292 wds:Q37976993-E78A2A1E-0D96-41B1-9DD1-222A06FC4E9B wds:Q37976993-EA389803-4CBD-4FD1-8A91-8A25C3673158 wds:Q37976993-ED70621B-C31C-42E7-9415-20DBBEAAFC1A wds:Q37976993-FB5B1909-D386-40E5-A7FA-CFB3DF5D9D0B wds:Q37976993-FCF9AE09-70AC-4AB6-9B65-C59B636C180D
cites work	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Toxicological and clinical computational analysis and the US FDA/CDER. The influence of drug-like concepts on decision-making in medicinal chemistry. A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models Recent advances in fragment-based QSAR and multi-dimensional QSAR methods Computational toxicology in drug development Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products Genetic toxicology in the 21st century: reflections and future directions Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors. Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action-Based Predictions of Chemical Carcinogenesis in Rodents. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Describing the validity of carcinogen screening tests In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. The current status and future applicability of quantitative structure-activity relationships (QSARs) in predicting toxicity. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities
author name string	wds:Q37976993-01672501-E15A-4C30-BB58-108C1A6BF88E wds:Q37976993-01D44BE4-FA60-4775-B5AB-C3EE851B3712 wds:Q37976993-E88DBD59-87D6-4915-9D0E-2206486430EB wds:Q37976993-F2748EE2-3BDC-4FC5-A293-634AE0D66681
author name string	H Zhou

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software